Vancouver, BC, January 23, 2023 /CNW/ – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA), is pleased to announce that its Nara Plant Library is now available on the Nara App as a resource for providing science-backed information. About natural treatment alternatives to pharmaceutical drugs. Pangenomic Health also announced that its Nara app now also complies with US Federal Trade Commission (“FTC”) guidelines.
in December 2022The US Federal Trade Commission (“FTC”) published its new Health Product Compliance Guidelines (“FTC Guidelines”)1which were updated for its 1998 publication Dietary Supplements: An Advertising Guide to the Industry, The expanded scope of the FTC guidelines now includes all health-related claims made in relation to foods, over-the-counter drugs, devices, and other health-related products, including consumer health apps. FTC guidelines require a “high level of scientific evidence” for products with any health claims related to consumer health.
“Pangenomic Health acknowledges the benefits that many pharmaceutical drugs provide to individuals with mental health conditions, but increasing consumer demand for natural alternatives and scientific uncertainty about the effectiveness of many pharmaceutical drugs, such as anti-depressant drugs Increasing”. mary marrison, President and CEO of Pangenomic Health. “As a result, Pangenomic Health developed its NARA app, as well as the nara.care website, to curate natural healing information for individuals and health practitioners. Government regulators like the FTC require science-backed confirmation for all of us Fully support the initiative of Health Claims.”
In a widely reported study published last year in Molecular Psychiatry, led by researchers from University College London, UK, Italian and Swiss researchers conducted a systematic review of the evidence for the serotonin chemical imbalance theory of depression. The researchers concluded that, “This review shows that the vast research effort based on the serotonin hypothesis has not provided convincing evidence of the biochemical basis of depression. This is consistent with research on many other biological markers. We suggest that It’s time to admit it. The serotonin theory of depression is not empirically proven.” 2
About Pangenomic Health
PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural remedies. The company’s initial focus is to support mental health. registered as British Columbia A for profit company, Pangenomic Health’s mission is to promote the health and well-being of individuals and societies by providing a technology platform that identifies plant-based solutions tailored to each individual’s health profile.
This news release contains certain statements that may be deemed “forward-looking statements,” including statements with respect to services to be provided by Pangenomic and consideration to be paid to Pangenomic. any words “estimates”, “continues”, “estimates”, “expects”, “may”, “will”, “will”, “project”, “should”, “believe” and similar expressions Use is intended to identify forward-looking statements. Although Pangenomic believes that the expectations and estimates on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Pangenomic can give no assurance that they will prove to be correct. In particular, there are no assurances regarding the future financial performance of PanGenomic Health. Future growth and the size of the general market for natural health products may not reflect Pangenomic Health’s future performance and there can be no assurance that Pangenomic Health will be able to capture any particular portion of those markets . Because forward-looking statements address future events and conditions, they by their very nature involve inherent risks and uncertainties. These statements speak only as of the date of this news release. In particular, there is no assurance that the Company will be able to sell any additional securities under the Offering. Actual results may differ materially from those currently anticipated due to a number of factors and risks, including various risk factors discussed in Pangenomic’s disclosure documents, which can be found under Pangenomic’s profile at www.sedar.com.
The Canadian Securities Exchange has neither approved nor disapproved of the information contained herein and accepts no responsibility for the adequacy or accuracy of this news release.
SOURCE Pangenomic Health Inc.
To download multimedia, see original content: http://www.newswire.ca/en/releases/archive/January2023/23/c0243.html